{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:37:42Z","timestamp":1790804262526,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00601","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T04:37:31Z","timestamp":1553747851000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["Evaluation of in vitro Assays to Assess the Modulation of Dendritic Cells Functions by Therapeutic Antibodies and Aggregates"],"prefix":"10.3389","volume":"10","author":[{"given":"Hannah","family":"Morgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Yi","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Gallais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margret","family":"Leineweber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Buchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Nabhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaahira","family":"Gani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Szely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia S.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kiessling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Werner","family":"Vohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pallardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Aswad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Turbica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"314","DOI":"10.4161\/self.1.4.13904","article-title":"Immunogenicity of protein therapeutics: the key causes, consequences and challenges","volume":"1","author":"Baker","year":"2010","journal-title":"Self Nonself."},{"key":"B2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat Publishing Group."},{"key":"B3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/01.TP.0000073809.65502.8F","article-title":"Anaphylactic shock caused by immunoglobulin e sensitization after retreatment with the chimeric anti \u2013 interleukin-2 receptor monoclonal antibody","volume":"76","author":"Baudouin","year":"2003","journal-title":"Transplantation."},{"key":"B4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1398-9995.2009.02280.x","article-title":"Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions","volume":"65","author":"Vultaggio","year":"2010","journal-title":"Allergy."},{"key":"B5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000336839","article-title":"Drug-specific Th2 cells and IgE antibodies in a patient with anaphylaxis to rituximab","volume":"159","author":"Vultaggio","year":"2012","journal-title":"Int Arch Allergy Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrug Antibodies (ADAb) to Tumour Necrosis Factor (TNF) specific neutralising agents in chronic inflammatory diseases : a real issue, a clinical perspective","volume":"72","author":"Vincent","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/ard.2009.109041","article-title":"Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis","volume":"69","author":"Thurlings","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"604872","DOI":"10.1155\/2015\/604872","article-title":"Influence of immunogenicity on the efficacy of long-term treatment with TNF\u03b1?","volume":"2015","author":"Arstikyte","year":"2015","journal-title":"s. Biomed Res Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-Up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA."},{"key":"B10","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3109\/00365521.2016.1157894","article-title":"Adalimumab trough serum levels and anti- adalimumab antibodies in the long-term clinical outcome of patients with crohn' s disease","volume":"51","author":"Bodini","year":"2016","journal-title":"Scand J Gastroenterol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology."},{"key":"B13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1023\/B:PHAM.0000029275.41323.a6","article-title":"Structure-immunogenicity relationships of therapeutic proteins","volume":"21","author":"Hermeling","year":"2004","journal-title":"Pharma. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1517\/17460441.2010.514326","article-title":"Immunogenicity of therapeutics: a matter of efficacy and safety","volume":"5","author":"Nechansky","year":"2010","journal-title":"Expert Opin Drug Discov."},{"key":"B15","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/jps.22276","article-title":"Impact of product-related factors on immunogenicity of biotherapeutics","volume":"100","author":"Singh","year":"2011","journal-title":"J Pharm Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2012.04.040","article-title":"Immunogenicity of protein aggregates \u2014 concerns and realities","volume":"431","author":"Wang","year":"2012","journal-title":"Int J Pharm."},{"key":"B17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/1547691X.2013.821564","article-title":"Immunogenicity of therapeutic proteins: influence of aggregation","volume":"11","author":"Ratanji","year":"2013","journal-title":"J Immunotoxicol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ijpharm.2010.02.025","article-title":"Protein aggregation\u2013pathways and influencing factors","volume":"390","author":"Wang","year":"2010","journal-title":"Int J Pharm."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/bit.23155","article-title":"Aggregates in monoclonal antibody manufacturing processes","volume":"108","author":"V\u00e1zquez-Rey","year":"2011","journal-title":"Biotechnol Bioeng"},{"key":"B20","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.tibtech.2014.05.005","article-title":"Therapeutic protein aggregation: mechanisms, design, and control","volume":"32","author":"Roberts","year":"2014","journal-title":"Trends Biotechnol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1208\/s12248-013-9510-6","article-title":"Immunogenicity of subcutaneously administered therapeutic proteins\u2014a mechanistic perspective","volume":"15","author":"Fathallah","year":"2013","journal-title":"AAPS J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.xphs.2016.09.028","article-title":"Microparticles and nanoparticles delivered in intravenous saline and in an intravenous solution of a therapeutic antibody product","volume":"106","author":"Pardeshi","year":"2017","journal-title":"J Pharm Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s11095-014-1472-6","article-title":"Investigation of the immunogenicity of different types of aggregates of a murine monoclonal antibody in mice","volume":"32","author":"Freitag","year":"2015","journal-title":"Pharm Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1007\/s11095-012-0749-x","article-title":"Detection and characterization of subvisible aggregates of monoclonal IgG in serum","volume":"29","author":"Filipe","year":"2012","journal-title":"Pharm Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11095-015-1627-0","article-title":"The immunogenicity of antibody aggregates in a novel transgenic mouse model","volume":"32","author":"Bessa","year":"2015","journal-title":"Pharm Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.xphs.2016.02.031","article-title":"Mouse models for assessing protein immunogenicity: lessons and challenges","volume":"105","author":"Jiskoot","year":"2016","journal-title":"J Pharm Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.xphs.2015.11.002","article-title":"Immunogenicity of therapeutic protein aggregates","volume":"105","author":"Moussa","year":"2016","journal-title":"J Pharm Sci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nri3582","article-title":"The function of Fc\u03b3 receptors in dendritic cells and macrophages","volume":"14","author":"Guilliams","year":"2014","journal-title":"Nat Rev Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5998","DOI":"10.4049\/jimmunol.164.11.5998","article-title":"No title differential expression and regulation of Toll-like Receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells","volume":"164","author":"Muzio","year":"2000","journal-title":"J Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.imlet.2005.11.023","article-title":"Expression and role of Fc- and complement-receptors on human dendritic cells","volume":"104","author":"Bajtay","year":"2006","journal-title":"Immunol Lett."},{"key":"B31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.4161\/mabs.1.5.9631","article-title":"Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fc \u03b3 receptors","volume":"1","author":"Luo","year":"2009","journal-title":"MAbs"},{"key":"B32","doi-asserted-by":"publisher","first-page":"25266","DOI":"10.1074\/jbc.M111.330902","article-title":"Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses","volume":"287","author":"Joubert","year":"2012","journal-title":"J Biol Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e86322","DOI":"10.1371\/journal.pone.0086322","article-title":"Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro","volume":"9","author":"Rombach-Riegraf","year":"2014","journal-title":"PLoS ONE."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s11095-014-1541-x","article-title":"Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics","volume":"32","author":"Ahmadi","year":"2014","journal-title":"Pharm Res Oct"},{"key":"B35","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/icb.2016.100","article-title":"Effect of growth hormone and IgG aggregates on dendritic cells activation and T-cells polarization","volume":"95","author":"Gallais","year":"2016","journal-title":"Immunol. Cell Biol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jneuroim.2018.11.002","article-title":"Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis","volume":"326","author":"Jensen","year":"2019","journal-title":"J Neuroimmunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0159328","DOI":"10.1371\/journal.pone.0159328","article-title":"Use of in vitro assays to assess immunogenicity risk of antibody-based biotherapeutics","volume":"11","author":"Joubert","year":"","journal-title":"PLoS ONE."},{"key":"B38","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.it.2013.07.006","article-title":"Dendritic cells and other innate determinants of T helper cell polarisation","volume":"34","author":"Walsh","year":"2013","journal-title":"Trends Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1600-065X.2008.00718.x","article-title":"Inflammatory signals in dendritic cell activation and the induction of adaptive immunity","volume":"227","author":"Joffre","year":"2009","journal-title":"Immunol Rev"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/jps.24379","article-title":"Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting","volume":"104","author":"Telikepalli","year":"2015","journal-title":"J Pharm Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri2206","article-title":"Fc\u03b3 receptors as regulators of immune responses","volume":"8","author":"Nimmerjahn","year":"2008","journal-title":"Nat Rev Immunol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/j.1365-2362.2011.02541.x","article-title":"2011 ESCI award for excellence in basic\/translational research: innate regulation of adaptive immunity by dendritic cells","volume":"41","author":"Reis e Sousa","year":"2011","journal-title":"Eur J Clin Invest."},{"key":"B43","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/ni1460","article-title":"Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce Interleukin 17","volume":"8","author":"LeibundGut-Landmann","year":"2007","journal-title":"Nat Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/ni.2366","article-title":"IL-12 family cytokines: immunological playmakers","volume":"13","author":"Vignali","year":"2012","journal-title":"Nat Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1182\/blood-2005-03-1252","article-title":"DC-SIGN ligation on dendritic cells results in ERK and PI3K activation and modulates cytokine production","volume":"107","author":"Caparr\u00f3s","year":"2006","journal-title":"Blood."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jdermsci.2005.11.004","article-title":"Differential role of MAPK signaling in human dendritic cell maturation and Th1\/Th2 engagement","volume":"42","author":"Nakahara","year":"2006","journal-title":"J Dermatol Sci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"32124","DOI":"10.1074\/jbc.M203298200","article-title":"The Phosphatidylinositol 3-Kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells","volume":"277","author":"Guha","year":"2002","journal-title":"J Biol Chem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1080\/19420862.2017.1320463","article-title":"Infliximab crystal structures reveal insights into self-association","volume":"9","author":"Lerch","year":"2017","journal-title":"MAbs."},{"key":"B49","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4161\/mabs.2.3.11782","article-title":"Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies","volume":"2","author":"Brennan","year":"2010","journal-title":"MAbs"},{"key":"B50","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/BOR.0b013e3283521c4e","article-title":"Immunogenicity of biological therapeutics: from assay to patient","volume":"24","author":"Krieckaert","year":"2012","journal-title":"Curr Opin Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00601\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T04:37:33Z","timestamp":1553747853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00601\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2019.00601"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00601","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,28]]},"article-number":"601"}}